{"nctId":"NCT00106704","briefTitle":"Sulfonylurea Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-035)","startDateStruct":{"date":"2005-03"},"conditions":["Diabetes Mellitus, Type 2"],"count":441,"armGroups":[{"label":"Sitagliptin","type":"EXPERIMENTAL","interventionNames":["Drug: Comparator: Sitagliptin"]},{"label":"Placebo/ Pioglitazone","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Comparator: Placebo","Drug: Comparator: Pioglitazone"]}],"interventions":[{"name":"Comparator: Sitagliptin","otherNames":[]},{"name":"Comparator: Placebo","otherNames":[]},{"name":"Comparator: Pioglitazone","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients with Type 2 Diabetes Mellitus with inadequate glycemic control\n\nExclusion Criteria:\n\n* Patients with Type 1 Diabetes Mellitus","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in A1C at Week 24","description":"Hemoglobin A1C (A1C) is measured as percent. Thus this change from baseline reflects the Week 24 A1C percent minus the Week 0 A1C percent.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.45","spread":null},{"groupId":"OG001","value":"0.28","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in FPG at Week 24","description":"The change from baseline is the Week 24 Fasting Plasma Glucose (FPG) minus the Week 0 FPG.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.4","spread":null},{"groupId":"OG001","value":"15.7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":17,"n":222},"commonTop":["Hypoglycaemia","Upper Respiratory Tract Infection","Nasopharyngitis","Headache","Urinary Tract Infection"]}}}